Position in GRFS
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,741
-$7,931 QoQ
Shares Held
246
-79.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#144
of 164 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Larson Financial Group LLC holds $64,664,035 across 17 Drug Manufacturers - General names. GRFS ranks #17 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
21,831 | $26,184,758 | |
| 2 | ABBV |
AbbVie Inc.
|
35,918 | $9,038,405 | |
| 3 | MRK |
Merck & Co., Inc.
|
63,932 | $8,215,262 | |
| 4 | PFE |
Pfizer Inc
|
310,250 | $7,470,820 | |
| 5 | JNJ |
Johnson & Johnson
|
27,845 | $7,071,794 | |
| 6 | AMGN |
Amgen Inc
|
7,025 | $2,543,893 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
25,994 | $1,497,774 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
11,716 | $1,480,199 |
All Filings in GRFS
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,741 | 246 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $9,672 | 1,206 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $6,563 | 702 | Shares | Sole | 2026-02-06 | |
| 2025-09-30 | $9,352 | 939 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $2,061 | 228 | Shares | Sole | 2025-08-08 | |
| No filing history on record for this holder in this stock. | ||||||